Abstract
Currently, the multiple sclerosis (MS) is the second most common cause of disability in young people after injury [1]. Approximately 85 % of patients with MS have a relapsing course, which in a half of cases occurs within 15–20 years, culminating in steady progression with or without activity remaining in the form of an exacerbation or new active foci. Diagnosis of secondary progressive MS (SPMS) is difficult and the diagnosis of SPMS is made retrospectively. Therefore, in our article, we considered options for reliable and objective biomarkers that are natural predictors of conversion and are sources for long-term prediction of diseases.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
